输注伊洛前列素（一种前列环素类似物）用于治疗系统性硬化症中的雷诺现象。
Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.
作者信息
McHugh N J, Csuka M, Watson H, Belcher G, Amadi A, Ring E F, Black C M, Maddison P J
机构信息
Royal National Hospital for Rheumatic Diseases, Bath, UK.
出版信息
Ann Rheum Dis. 1988 Jan;47(1):43-7. doi: 10.1136/ard.47.1.43.
Abstract
Iloprost, a stable prostacyclin analogue, was given by intravenous infusion to 29 patients with severe Raynaud's phenomenon, 26 of whom had systemic sclerosis (SS), and compared with placebo infusion in a double blind crossover trial. Iloprost significantly lessened the number and the severity of attacks compared with placebo. Nine patients expressed a preference for effectiveness of treatment, eight of these in favour of Iloprost. Thermography failed to show any long term effect of Iloprost. Side effects of headache, flushing, nausea, and vomiting were common, and the inconvenience of intravenous administration may limit its routine use.
摘要
依洛前列素是一种稳定的前列环素类似物，在一项双盲交叉试验中，对29例患有严重雷诺现象的患者进行静脉输注，其中26例患有系统性硬化症（SS），并与安慰剂输注进行比较。与安慰剂相比，依洛前列素显著减少了发作的次数和严重程度。9例患者表示更喜欢治疗的有效性，其中8例支持依洛前列素。热成像未能显示依洛前列素的任何长期效果。头痛、潮红、恶心和呕吐等副作用很常见，静脉给药的不便可能会限制其常规使用。
相似文献
1
Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.输注伊洛前列素（一种前列环素类似物）用于治疗系统性硬化症中的雷诺现象。
Ann Rheum Dis. 1988 Jan;47(1):43-7. doi: 10.1136/ard.47.1.43.
2
Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.静脉输注伊洛前列素与口服硝苯地平治疗系统性硬化症患者雷诺现象的比较：一项双盲随机研究。
BMJ. 1989 Mar 4;298(6673):561-4. doi: 10.1136/bmj.298.6673.561.
3
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.口服伊洛前列素治疗系统性硬化症继发雷诺现象患者：一项多中心、安慰剂对照、双盲研究。
Arthritis Rheum. 1998 Apr;41(4):670-7. doi: 10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I.
4
[Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative].
Dtsch Med Wochenschr. 1984 Sep 21;109(38):1433-8. doi: 10.1055/s-2008-1069390.
5
Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.口服伊洛前列素治疗系统性硬化症继发雷诺现象：一项多中心、安慰剂对照、剂量比较研究。
Br J Rheumatol. 1998 Sep;37(9):952-60. doi: 10.1093/rheumatology/37.9.952.
6
Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.静脉注射伊洛前列素治疗系统性硬化症继发的雷诺现象和缺血性溃疡。
J Rheumatol. 1992 Sep;19(9):1407-14.
7
8
Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.静脉输注伊洛前列素治疗系统性硬化症继发雷诺现象。一项多中心、安慰剂对照、双盲研究。
Ann Intern Med. 1994 Feb 1;120(3):199-206. doi: 10.7326/0003-4819-120-3-199402010-00004.
9
Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.伊洛前列素和顺前列素治疗进行性系统性硬化症中的雷诺现象。
Cochrane Database Syst Rev. 2000;1998(2):CD000953. doi: 10.1002/14651858.CD000953.
10
[Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].[长期伊洛前列素治疗对进行性系统性硬化症雷诺现象的影响]
Minerva Med. 1992 Nov;83(11):739-44.
引用本文的文献
1
2023 Brazilian Society of Rheumatology guidelines for the treatment of systemic sclerosis.2023 年巴西风湿病学会系统性硬化症治疗指南。
Adv Rheumatol. 2024 Jul 10;64(1):52. doi: 10.1186/s42358-024-00392-w.
2
Practice pattern for the use of intravenous iloprost for the treatment of peripheral vasculopathy in systemic sclerosis: A case-control study from the Italian national multicenter "SPRING" (Systemic Sclerosis Progression InvestiGation) Registry.静脉注射伊洛前列素治疗系统性硬化症外周血管病变的实践模式：来自意大利国家多中心“SPRING”（系统性硬化症进展研究）注册中心的病例对照研究。
J Scleroderma Relat Disord. 2024 Feb;9(1):38-49. doi: 10.1177/23971983231209809. Epub 2024 Jan 11.
3
Real life use of prostacyclin analog (iloprost), a multi-centric survey data from the Scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature.前列环素类似物（依前列醇）的实际应用：来自艾米利亚-罗马涅硬皮病研究组（Sclero-RER）的多中心调查数据和文献复习。
Acta Biomed. 2023 Aug 3;94(4):e2023148. doi: 10.23750/abm.v94i4.14317.
4
Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon.系统性硬皮病相关雷诺现象的高光谱成像。
Arthritis Res Ther. 2023 Jan 20;25(1):10. doi: 10.1186/s13075-023-02990-3.
5
Iloprost Duration for Digital Ulcers in Systemic Sclerosis: French Retrospective Study at Two Centers and Literature Review.伊洛前列素治疗系统性硬化症指端溃疡的疗程：法国两个中心的回顾性研究及文献综述
Front Med (Lausanne). 2022 Jul 6;9:878970. doi: 10.3389/fmed.2022.878970. eCollection 2022.
6
Patient-reported outcome instruments in clinical trials of systemic sclerosis.系统性硬化症临床试验中的患者报告结局指标
J Scleroderma Relat Disord. 2020 Jun;5(2):90-102. doi: 10.1177/2397198319886496. Epub 2019 Nov 25.
7
A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis.一项为期 4 周的比较研究：在系统性硬化症的难治性指端溃疡中，肉毒杆菌毒素 A 与前列环素类似物输注的毛细血管变化、愈合效果和成本效益比较。
Clin Rheumatol. 2022 Jan;41(1):95-104. doi: 10.1007/s10067-021-05900-7. Epub 2021 Sep 1.
8
An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.系统性硬皮病的药物治疗选择和治疗策略的最新进展。
Expert Opin Pharmacother. 2020 Nov;21(16):2041-2056. doi: 10.1080/14656566.2020.1793960. Epub 2020 Jul 17.
9
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study.意大利三级转诊中心伊洛前列素的使用和与系统性硬皮病相关的血管病变的医学治疗：PROSIT 研究的结果。
Clin Exp Med. 2019 Aug;19(3):357-366. doi: 10.1007/s10238-019-00553-y. Epub 2019 Apr 15.
10
Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis.多国定性研究探索系统性硬化症患者雷诺现象的体验。
Arthritis Care Res (Hoboken). 2018 Sep;70(9):1373-1384. doi: 10.1002/acr.23475. Epub 2018 Aug 16.
本文引用的文献
1
Treatment of vasospastic disease with prostaglandin E1.用前列腺素E1治疗血管痉挛性疾病。
Br Med J. 1980 Oct 18;281(6247):1031-4. doi: 10.1136/bmj.281.6247.1031.
2
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.系统性硬化症（硬皮病）分类的初步标准。美国风湿病协会诊断与治疗标准委员会硬皮病标准小组委员会。
Arthritis Rheum. 1980 May;23(5):581-90. doi: 10.1002/art.1780230510.
3
Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome.
J Int Med Res. 1981;9(6):393-400. doi: 10.1177/030006058100900601.
4
Hyperviscosity and thrombotic changes in idiopathic and secondary Raynaud's syndrome.特发性和继发性雷诺综合征中的高黏滞血症和血栓形成变化
Br J Haematol. 1980 Aug;45(4):651-8. doi: 10.1111/j.1365-2141.1980.tb07188.x.
5
The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374)--equipotent to PGI2 in vitro.一种新型卡前列素衍生物（ZK 36 374）的抗血小板和心血管作用——在体外与前列环素（PGI2）等效。
Naunyn Schmiedebergs Arch Pharmacol. 1981 Jun;316(3):252-5. doi: 10.1007/BF00505658.
6
Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.雷尼尔氏综合征患者间歇性输注依前列醇（前列环素）：一项双盲对照试验。
Lancet. 1983 Feb 12;1(8320):313-5. doi: 10.1016/s0140-6736(83)91624-0.
7
Prostaglandin E1 vasospastic disease and thermography.前列腺素E1、血管痉挛性疾病与热成像
Ann Rheum Dis. 1985 Feb;44(2):73-8. doi: 10.1136/ard.44.2.73.
8
Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of patients with progressive scleroderma.
Arch Dermatol Res. 1985;277(4):323-5. doi: 10.1007/BF00509089.
9
The two-period cross-over clinical trial.两阶段交叉临床试验。
Br J Clin Pharmacol. 1979 Jul;8(1):7-20. doi: 10.1111/j.1365-2125.1979.tb05903.x.
Zotero 插件